Novocure
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States. From 1998 to 2002, Mr. Danziger was Chief Executive Officer of Cybro Medical, a subsidiary of Imagyn Medical Technologies. Mr. Danziger holds a B.Sc. in material engineering from Ben Gurion University of the Negev, Israel.
This person is not in any offices
Novocure
3 followers
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma.